Stock Information
Share Data
Stock Performance
Analyst Coverage
Advisor & Investor Contacts

Reports & Presentations

Interim & Annual Reports
Presentations
Corporate Governance
Company Information
Leadership
Board of Directors
General Meetings

Media

SEC Filings
News

About

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company’s lead development programme, eRapa™, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection. Without effective treatment virtually all FAP patients progress to develop colorectal cancer. The company is also working on treatments for type 1 diabetes and primary and metastatic cancers of the brain.

eRapa is a proprietary oral tablet formulation of rapamycin (sirolimus). Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR is known to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis. Rapamycin is approved in the US for organ rejection in renal transplantation. It is very poorly water soluble and current formulations exhibit significant variability in systemic plasma levels. Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to improve bioavailability and achieve more consistent pharmacokinetics than existing products.

Tolimidone is an orally delivered, potent and selective activator of lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.

MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.

biodexa scientist at work
woman on beach

Our Mission

Our mission is to advance medicines that will provide a brighter future for patients with serious conditions that are not fully served by existing treatments.

Leadership

Core to Biodexa Pharmaceuticals strength is its highly experienced and dedicated team.

The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.

Stephen Stamp

Stephen Stamp

CEO / CFO

Dmitry Zamoryakhin

Dmitry Zamoryakhin

Chief Scientific Officer/Chief Medical Officer

Dan Palmer

Dan Palmer

VP Technology

Fiona Sharp

Fiona Sharp

Group Financial Controller

Steve Ellul

Steve Ellul

Chief Business Officer

Nicola Tuckwell

Nicola Tuckwell

VP Head of Clinical Operations

Board of Directors

 Stephen Parker

Stephen Parker

Non-executive Chairman

Stephen Stamp

Stephen Stamp

CEO / CFO

Simon Turton

Simon Turton

Senior Independent Non-executive Director

Sijmen de Vries

Sijmen de Vries

Non-executive Director

Ann Merchant

Ann Merchant

Non-executive Director